drugset

drugset / Trial / NCT02608970

Safety and Tolerability Study of BMS-986177 in Healthy Subjects

NCT02608970 ↗

Phase 1 Completed 104 enrolled Bristol-Myers Squibb

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine the safety, tolerability, and pharmacokinetics of BMS-986177 in healthy subjects

Timeline

Start: 2015-12-31
Primary completion: 2017-07-23
Completion: 2017-07-23

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Milvexian	Small molecule	—	—

Indications